Johnson & Johnson Aktie
WKN: 853260 / ISIN: US4781601046
17.03.2020 16:34:34
|
J&J Says No Proof To Support Use Of Darunavir For COVID-19
(RTTNews) - Johnson and Johnson (JNJ) has revealed that there is no evidence to support the use of Darunavir for the treatment of COVID-19. There have been anecdotal, unsubstantiated reports claiming that Darunavir has antiviral effects against the novel coronavirus.
Darunavir, sold under brand name Prezista, is used in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV) infection and is marketed by JNJ's subsidiary Janssen Pharmaceutical.
The Company is screening its antiviral compounds, including Darunavir, to determine potential in vitro effect against SARS-CoV-2.
Janssen has also provided Darunavir-based medicines to support three clinical studies in China. As soon as the data become available, the Company will be updating the information.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Johnson & Johnsonmehr Nachrichten
09.04.25 |
Freundlicher Handel in New York: Dow Jones letztendlich auf Höhenflug (finanzen.at) | |
09.04.25 |
Zuversicht in New York: Dow Jones hebt am Nachmittag ab (finanzen.at) | |
09.04.25 |
Verluste in New York: Dow Jones liegt am Mittag im Minus (finanzen.at) | |
09.04.25 |
Gewinne in New York: Dow Jones steigt zum Handelsstart (finanzen.at) | |
08.04.25 |
Börse New York: Dow Jones verbucht am Dienstagmittag Zuschläge (finanzen.at) | |
04.04.25 |
Schwacher Handel: Dow Jones beginnt die Sitzung weit in der Verlustzone (finanzen.at) | |
03.04.25 |
Verluste in New York: Dow Jones stürzt zum Ende des Donnerstagshandels ab (finanzen.at) | |
03.04.25 |
Verluste in New York: So entwickelt sich der Dow Jones am Nachmittag (finanzen.at) |
Analysen zu Johnson & Johnsonmehr Analysen
Aktien in diesem Artikel
Johnson & Johnson | 131,22 | -1,20% |
|